JP7386536B2 - アルキル鎖修飾イミダゾキノリンtlr7/8アゴニスト化合物およびその使用 - Google Patents

アルキル鎖修飾イミダゾキノリンtlr7/8アゴニスト化合物およびその使用 Download PDF

Info

Publication number
JP7386536B2
JP7386536B2 JP2020511364A JP2020511364A JP7386536B2 JP 7386536 B2 JP7386536 B2 JP 7386536B2 JP 2020511364 A JP2020511364 A JP 2020511364A JP 2020511364 A JP2020511364 A JP 2020511364A JP 7386536 B2 JP7386536 B2 JP 7386536B2
Authority
JP
Japan
Prior art keywords
compound
pharmaceutical composition
salt
methyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020511364A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020531530A5 (cg-RX-API-DMAC7.html
JP2020531530A (ja
Inventor
スチュワート ディー. チップマン,
ジョン デマッテイ,
ラドワン キワン,
メリッサ エー. カチューラ,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dynavax Technologies Corp
Original Assignee
Dynavax Technologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dynavax Technologies Corp filed Critical Dynavax Technologies Corp
Publication of JP2020531530A publication Critical patent/JP2020531530A/ja
Publication of JP2020531530A5 publication Critical patent/JP2020531530A5/ja
Priority to JP2023121658A priority Critical patent/JP2023129623A/ja
Application granted granted Critical
Publication of JP7386536B2 publication Critical patent/JP7386536B2/ja
Priority to JP2025083816A priority patent/JP2025131620A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
JP2020511364A 2017-08-22 2018-08-21 アルキル鎖修飾イミダゾキノリンtlr7/8アゴニスト化合物およびその使用 Active JP7386536B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023121658A JP2023129623A (ja) 2017-08-22 2023-07-26 アルキル鎖修飾イミダゾキノリンtlr7/8アゴニスト化合物およびその使用
JP2025083816A JP2025131620A (ja) 2017-08-22 2025-05-20 アルキル鎖修飾イミダゾキノリンtlr7/8アゴニスト化合物およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762548848P 2017-08-22 2017-08-22
US62/548,848 2017-08-22
PCT/US2018/047323 WO2019040491A1 (en) 2017-08-22 2018-08-21 MODIFIED ALKYL CHAIN IMIDAZOQUINOLINE TLR7 / 8 AGONIST COMPOUNDS AND USES THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023121658A Division JP2023129623A (ja) 2017-08-22 2023-07-26 アルキル鎖修飾イミダゾキノリンtlr7/8アゴニスト化合物およびその使用

Publications (3)

Publication Number Publication Date
JP2020531530A JP2020531530A (ja) 2020-11-05
JP2020531530A5 JP2020531530A5 (cg-RX-API-DMAC7.html) 2021-09-16
JP7386536B2 true JP7386536B2 (ja) 2023-11-27

Family

ID=63638354

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020511364A Active JP7386536B2 (ja) 2017-08-22 2018-08-21 アルキル鎖修飾イミダゾキノリンtlr7/8アゴニスト化合物およびその使用
JP2023121658A Pending JP2023129623A (ja) 2017-08-22 2023-07-26 アルキル鎖修飾イミダゾキノリンtlr7/8アゴニスト化合物およびその使用
JP2025083816A Pending JP2025131620A (ja) 2017-08-22 2025-05-20 アルキル鎖修飾イミダゾキノリンtlr7/8アゴニスト化合物およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023121658A Pending JP2023129623A (ja) 2017-08-22 2023-07-26 アルキル鎖修飾イミダゾキノリンtlr7/8アゴニスト化合物およびその使用
JP2025083816A Pending JP2025131620A (ja) 2017-08-22 2025-05-20 アルキル鎖修飾イミダゾキノリンtlr7/8アゴニスト化合物およびその使用

Country Status (5)

Country Link
US (4) US10618896B2 (cg-RX-API-DMAC7.html)
EP (2) EP4257198A3 (cg-RX-API-DMAC7.html)
JP (3) JP7386536B2 (cg-RX-API-DMAC7.html)
ES (1) ES2951817T3 (cg-RX-API-DMAC7.html)
WO (1) WO2019040491A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4257198A3 (en) * 2017-08-22 2023-10-18 Dynavax Technologies Corporation Alkyl chain modified imidazoquinoline derivatives as tlr7/8 agonists and uses thereof
US10722591B2 (en) 2017-11-14 2020-07-28 Dynavax Technologies Corporation Cleavable conjugates of TLR7/8 agonist compounds, methods for preparation, and uses thereof
BR112021015577A2 (pt) 2019-02-08 2021-10-05 Research & Business Foundation Sungkyunkwan University Complexo-colesterol agonista do receptor toll-like 7 ou 8 e uso do mesmo
BR112022008039A2 (pt) 2019-10-29 2022-07-12 Prime Reach Trading Ltd Compostos de 4-amino-imidazoquinolina e usos relacionados
CN115666637A (zh) 2020-03-02 2023-01-31 蛋白科技先锋 基于病原体细胞壁骨架的模拟活病原体的纳米粒子及其制备方法
EP4146204A4 (en) * 2020-05-05 2024-07-03 Virovax LLC Vaccine adjuvants
EP4194008A4 (en) 2020-08-04 2025-01-08 Progeneer Inc. Kinetically acting adjuvant ensemble
WO2022031021A1 (ko) 2020-08-04 2022-02-10 성균관대학교산학협력단 동력학적 제어가 가능한 아주번트를 포함하는 mrna 백신
US20230277525A1 (en) 2020-08-04 2023-09-07 Progeneer Inc Conjugate of functional drug and toll-like receptor 7 or 8 agonist of which active site is temporarily inactivated and use thereof
CN113967256B (zh) * 2021-10-26 2022-09-30 山东大学 一种具有光热-化疗-免疫功能的纳米粒及其制备方法和应用
US20250025447A1 (en) * 2021-11-03 2025-01-23 Regents Of The University Of Minnesota Toll-like receptor agonists and antagonists and uses thereof
WO2023086890A1 (en) * 2021-11-10 2023-05-19 The University Of Chicago Small molecule immunopotentiator conjugates of nfkb activators as adjuvants with enhanced efficacy and reduced toxicity
CN116731015B (zh) * 2023-05-18 2024-09-27 深圳威科森生物医药科技有限公司 咪唑并喹啉化合物及其制备方法、应用和组合物
EP4731632A1 (en) * 2023-06-21 2026-04-29 The Trustees of The University of Pennsylvania Toll-like receptor (tlr) agonist lipidoid compounds, lipid nanoparticles (lnps) comprising the same, and methods of use thereof
WO2025110816A1 (ko) 2023-11-23 2025-05-30 프로지니어 주식회사 암의 치료를 위한 활성화 부위가 일시적으로 비활성화된 톨-유사 수용체 7 또는 8 작용자와 항암 치료의 병용요법
WO2026046400A1 (zh) * 2024-08-30 2026-03-05 惠正奇生物技术(广州)有限公司 含杂芳环结构的脂质类化合物及其应用
CN119320387B (zh) * 2024-12-19 2025-06-27 杭州天龙药业有限公司 基于Toll样受体激动剂的疫苗佐剂脂质化合物及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120294885A1 (en) 2011-05-18 2012-11-22 The University Of Kansas Toll-like receptor-7 and -8 modulatory 1h imidazoquinoline derived compounds
JP2013512859A (ja) 2009-12-03 2013-04-18 大日本住友製薬株式会社 トール様受容体(tlr)を介して作用するイミダゾキノリン
WO2017058996A1 (en) 2015-09-29 2017-04-06 The University Of Chicago Polymer conjugate vaccines
JP2020532571A (ja) 2017-09-06 2020-11-12 バイオエヌテック エスエーBiontech Se Tlr7のアゴニストとしての置換イミダゾキノリン
JP2021503005A (ja) 2017-11-14 2021-02-04 ダイナバックス テクノロジーズ コーポレイション Tlr7/8アゴニスト化合物の切断可能なコンジュゲート、その調製方法および使用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
DK0708772T3 (da) 1993-07-15 2000-09-18 Minnesota Mining & Mfg Imidazo[4,5,-c]pyridin-4-aminer
JPH1180156A (ja) 1997-09-04 1999-03-26 Hokuriku Seiyaku Co Ltd 1−(置換アリール)アルキル−1h−イミダゾピリジン−4−アミン誘導体
UA67760C2 (uk) 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
US6180095B1 (en) 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
HUP0201425A3 (en) 1999-04-23 2006-07-28 Hadasit Med Res Service Conjugate having a cleavable linkage for use in a liposome
US7238368B2 (en) 1999-04-23 2007-07-03 Alza Corporation Releasable linkage and compositions containing same
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
WO2004032829A2 (en) 2002-08-15 2004-04-22 3M Innovative Properties Company Immunostimulatory compositions and methods of stimulating an immune response
US6818650B2 (en) 2002-09-26 2004-11-16 3M Innovative Properties Company 1H-imidazo dimers
JP2006513212A (ja) 2002-12-20 2006-04-20 スリーエム イノベイティブ プロパティズ カンパニー アリール/ヘタリール置換されたイミダゾキノリン
US7387271B2 (en) 2002-12-30 2008-06-17 3M Innovative Properties Company Immunostimulatory combinations
JP2006517974A (ja) 2003-02-13 2006-08-03 スリーエム イノベイティブ プロパティズ カンパニー Irm化合物およびトル様受容体8に関する方法および組成物
AU2004229478B2 (en) 2003-04-10 2009-12-24 3M Innovative Properties Company Delivery of immune response modifier compounds
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
CA2535338C (en) 2003-08-14 2013-05-28 3M Innovative Properties Company Substituted 1h-imidazo[4,5-c]pyridin-4-amines,1h-imidazo[4,5-c]quinolin -4-amines and 1h-imidazo[4,5-c]naphthyridin-4-amines as immune response modifiers
RU2006121646A (ru) 2003-11-21 2008-01-10 Новартис АГ (CH) Производные 1h-имидазохинолина в качестве ингибиторов протеинкиназы
EP1765348B1 (en) 2004-06-18 2016-08-03 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
WO2007079086A1 (en) 2005-12-28 2007-07-12 Coley Pharmaceutical Group, Inc. Pyrazoloalkyl substituted imidazo ring compounds and methods
EP1988896A4 (en) 2006-02-22 2011-07-27 3M Innovative Properties Co CONJUGATES TO MODIFY IMMUNE REACTIONS
US9556167B2 (en) 2012-05-02 2017-01-31 Yale University TLR-agonist-conjugated antibody recruiting molecules (TLR-ARMs)
EP2674170B1 (en) 2012-06-15 2014-11-19 Invivogen Novel compositions of TLR7 and/or TLR8 agonists conjugated to lipids
EP2732825B1 (en) 2012-11-19 2015-07-01 Invivogen Conjugates of a TLR7 and/or TLR8 agonist and a TLR2 agonist
WO2014113634A1 (en) 2013-01-17 2014-07-24 University Of Kansas Toll-like receptor 2-agonistic lipopeptides, and method of making the same
EP2769738B1 (en) 2013-02-22 2016-07-20 Invivogen Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists
US10471139B2 (en) 2013-08-15 2019-11-12 The University Of Kansas Toll-like receptor agonists
GB201321242D0 (en) 2013-12-02 2014-01-15 Immune Targeting Systems Its Ltd Immunogenic compound
EP3092256B1 (en) 2014-01-10 2022-05-18 Birdie Biopharmaceuticals Inc. Compounds and compositions for immunotherapy
SG11201608299TA (en) 2014-05-01 2016-11-29 Novartis Ag Compounds and compositions as toll-like receptor 7 agonists
GB201418004D0 (en) 2014-10-10 2014-11-26 Isis Innovation Polymer adjuvant
WO2017044803A1 (en) 2015-09-09 2017-03-16 The United States Of America, As Represented By The Secretary Department Of Health And Human Service Expression vector delivery system and use thereof for inducing an immune response
CR20180229A (es) 2015-10-29 2018-08-24 Novartis Ag Conjugados de anticuerpos que comprenden un agonista del receptor tipo toll
WO2018112108A1 (en) 2016-12-13 2018-06-21 Bolt Biotherapeutics, Inc. Antibody adjuvant conjugates
US10328895B2 (en) 2017-03-17 2019-06-25 Autoliv Asp, Inc. Seatbelt pretensioning retractor assembly including a pretensioner rod
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
US20180311334A1 (en) 2017-04-29 2018-11-01 Yale University Compositions and Methods for Inducing an Immune Response
EP4257198A3 (en) 2017-08-22 2023-10-18 Dynavax Technologies Corporation Alkyl chain modified imidazoquinoline derivatives as tlr7/8 agonists and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013512859A (ja) 2009-12-03 2013-04-18 大日本住友製薬株式会社 トール様受容体(tlr)を介して作用するイミダゾキノリン
US20120294885A1 (en) 2011-05-18 2012-11-22 The University Of Kansas Toll-like receptor-7 and -8 modulatory 1h imidazoquinoline derived compounds
WO2017058996A1 (en) 2015-09-29 2017-04-06 The University Of Chicago Polymer conjugate vaccines
JP2020532571A (ja) 2017-09-06 2020-11-12 バイオエヌテック エスエーBiontech Se Tlr7のアゴニストとしての置換イミダゾキノリン
JP2021503005A (ja) 2017-11-14 2021-02-04 ダイナバックス テクノロジーズ コーポレイション Tlr7/8アゴニスト化合物の切断可能なコンジュゲート、その調製方法および使用

Also Published As

Publication number Publication date
US11124510B2 (en) 2021-09-21
US20240368155A1 (en) 2024-11-07
EP4257198A2 (en) 2023-10-11
JP2023129623A (ja) 2023-09-14
EP4257198A3 (en) 2023-10-18
US20190062329A1 (en) 2019-02-28
EP3672969B1 (en) 2023-07-05
EP3672969A1 (en) 2020-07-01
US11981670B2 (en) 2024-05-14
ES2951817T3 (es) 2023-10-25
WO2019040491A1 (en) 2019-02-28
US10618896B2 (en) 2020-04-14
JP2020531530A (ja) 2020-11-05
JP2025131620A (ja) 2025-09-09
US20220033400A1 (en) 2022-02-03
US20200199124A1 (en) 2020-06-25

Similar Documents

Publication Publication Date Title
US11981670B2 (en) Alkyl chain modified imidazoquinoline TLR7/8 agonist compounds and uses thereof
JP6710727B2 (ja) 脂質付加された免疫反応調節化合物の組成物、製剤及び方法
JP6257607B2 (ja) 癌免疫療法のための組成物および方法
CN108290845B (zh) 嘧啶化合物
EP1874342B1 (en) Compositions and methods for cancer immunotherapy
WO2005120574A1 (ja) 調節性細胞リガンドをリポソームに含有させてなる医薬
CN1921862A (zh) 包含至少一种toll样受体7或toll样受体8激动剂以及toll样受体4激动剂的免疫刺激组合物
CN114206378A (zh) 基于tlr受体配体的疫苗佐剂
KR102610798B1 (ko) 이중 규격 다공성 실리카 입자 기반의 암 예방 또는 치료용 조성물
Jyoti et al. played by nanoimmunoadjuvants
WO2025037627A1 (ja) Nkt細胞リガンド含有リポソーム組成物を含む抗がん剤
AU2018202168B2 (en) Lipidated immune response modifier compound compositions, formulations, and methods
CN116891828A (zh) 新型的免疫刺激分子及改造的外泌体及其制备方法和应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210805

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210805

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220706

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220707

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230105

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230726

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230804

TRDD Decision of grant or rejection written
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20231004

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231010

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20231018

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231107

R150 Certificate of patent or registration of utility model

Ref document number: 7386536

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150